4//SEC Filing
Aslan Fred 4
Accession 0001415889-25-022224
CIK 0001817241other
Filed
Aug 17, 8:00 PM ET
Accepted
Aug 18, 8:15 PM ET
Size
8.5 KB
Accession
0001415889-25-022224
Insider Transaction Report
Form 4
Aslan Fred
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
2025-05-15$2.13/sh−4,472$9,525→ 412,193 total - Sale
Common Stock
2025-08-15$2.73/sh−25,500$69,579→ 386,693 total - Tax Payment
Common Stock
2025-08-15$2.75/sh−4,472$12,298→ 382,221 total
Footnotes (3)
- [F1]Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
- [F2]Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 23, 2024, to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
- [F3]The weighted average sale price for the transaction reported was $2.7286, and the range of prices were between $2.60 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Artiva Biotherapeutics, Inc.
CIK 0001817241
Entity typeother
Related Parties
1- filerCIK 0001909362
Filing Metadata
- Form type
- 4
- Filed
- Aug 17, 8:00 PM ET
- Accepted
- Aug 18, 8:15 PM ET
- Size
- 8.5 KB